罗沙司他与重组人促红素治疗维持性血液透析患者肾性贫血的效果

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (565 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Roxathat and Recombinant Human Erythropoietin (hereinafter referred to as “erythropoietin”) in the treatment of renal anemia in maintenance hemodialysis patients. Methods A total of 60 patients with renal anemia admitted to the Central Hospital of Ma’anshan, Anhui Province from December 2019 to September 2020 were selected and they were divided into observation group and control group according to random number table method, with 30 patients in each group. The control group was treated with Recombinant Human Erythropoietin combined with Ferrous Succinate Sustained-release Tablets, and the observation group was treated with Roxathat combined with Ferrous Succinate Sustained-release Tablets. Both groups were treated for three months continuously. The changes of hemoglobin (Hb), red blood cell count (RBC), hematocrit (Hct), serum iron (SI), unsaturated iron-binding capacity (UIBC), total iron-binding capacity (TIBC), serum iron saturation (ISAT) before and after treatment and the incidence of adverse reactions were compared between two groups. Results After treatment, the levels of Hb, RBC, Hct, SI, TIBC and ISAT in both groups were higher than before treatment, and the observation group was higher than the control group, the differences were statistically significant (all P < 0.05). After treatment, the level of UIBC in the two groups was lower than that before treatment, and the level of UIBC in the observation group was lower than that in the control group, the differences were statistically significant (all P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Roxastat can more effectively improve the levels of anemia indexes and iron metabolism indexes of renal anemia in maintenance hemodialysis patients, which is safe and reliable and worthy of clinical promotion.

Key words： Maintenance hemodialysis Renal anemia Rosathostat Recombinant Human Erythropoietin Ferrous Succinate Sustained-release Tablets Erythropoietin Curative effect Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	FANG Lei HUANG Yangyang WU Xueqi

Cite this article:

FANG Lei HUANG Yangyang WU Xueqi. Effect of Roxathat and Recombinant Human Erythropoietin in the treatment of renal anemia in maintenance hemodialysis patients[J]. 中国医药导报, 2021, 18(11): 137-140.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I11/137

[1] 高术亮.血液灌流对维持性血液透析患者肾性贫血和微炎症状态的影响[J].医学理论与实践，2018，31（7）：69-70.
[2] 何舒宁，张亮亮，郝丽，等.维持性血液透析患者钙磷及iPTH三项指标达标状况分析[J].安徽医学，2020，41（2）：13-16.
[3] 王志菡，吴昌平，刘安文，等.重组人促红素注射液治疗肿瘤相关性贫血68例[J].中国新药杂志，2018，27（17）：2042-2046.
[4] 白荷荷，聂晓静，王园姬.297例重组人促红素及铁剂治疗血液透析肾性贫血的合理性评价[J].药物流行病学杂志，2018，27（6）：392-395.
[5] 谢院生，李清刚.肾脏病学临床研究新进展[J].中国中西医结合肾病杂志，2020，21（6）：471-473.
[6] 周雅萍，李凯.治疗肾性贫血新药罗沙司他[J].药物评价研究，2018，41（9）：1743-1748.
[7] 贺晓瑛，潘兴泉，李家国，等.治疗肾性贫血新药—roxadustat[J].临床药物治疗杂志，2018，16（8）：1-3.
[8] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识（2018修订版）[J].中华肾脏病杂志，2018，34（11）：860.
[9] 刘鑫阔，刘洋，文南萍，等.维持性血液透析患者高通量透析治疗肾性贫血疗效和安全性的Meta分析[J].疑难病杂志，2019，18（8）：841-846.
[10] Biggar P，Kim GH. Treatment of renal anemia：Erythropoiesis stimulating agents and beyond [J]. Kidney Res Clin Pract，2017，36（3）：209.
[11] 胡瑞钺，蔡立婧，杨建秋.临床药师干预对维持性血液透析患者肾性贫血影响[J].江西医药，2018，53（11）：21-23.
[12] Maruyama T，Higuchi T，Yamazaki T，et al. Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia [J]. Cardiorenal Medicine，2017，7（3）：188-197.
[13] London G，Mann J，Goldsmith D，et al. Long-term treatment with biosimilar epoetin-α（HX575） in hemodialysis patients with renal anemia： real-world effectiveness and safety in the MONITOR-CKD5 study [J]. Clinical Nephrology，2018，89（1）：1-9.
[14] 李梅，黄楠，杨春霞，等.影响长期维持性血液透析患者发生肾性贫血的危险因素分析[J].昆明医科大学学报，2019，40（10）：125-130.
[15] Maxwell PH，Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond [J]. Nat Rev Nephrol，2016，12（3）：157-168.
[16] 樊迪，路万虹，杨悦，等.促红细胞生成素及铁剂治疗肾性贫血的合理性评价[J].西北药学杂志，2016，31（3）：305-308.
[17] 郭冬慈，张宝桐.左卡尼汀联合促红细胞生成素及蔗糖铁治疗尿毒症行血液透析伴有肾性贫血的效果[J].中国当代医药，2020，27（35）：25-28.
[18] 李迪迪，穆柯，王军娜，等.重组人促红素治疗肾性贫血的疗效观察[J].临床医学，2020，40（8）：84-85.
[19] 梁矛锋，简汝堃，刘春花.大剂量促红细胞生成素治疗血液透析患者肾性贫血的效果及对血清铁蛋白、叶酸水平的影响研究[J].中国医药科学，2019，9（5）：60-62.
[20] 张靖华，王长安，黑小杰.还原型谷胱甘肽联合重组人促红素治疗尿毒症贫血患者的有效性与安全性[J].药物评价研究，2017，40（10）：1464-1467.
[21] 张其伟，周嘉第，陈永健，等.罗沙司他的合成研究进展[J].中国医药工业杂志，2019，50（11）：1237-1245.
[22] 张晓良，仰欣，涂岩.低氧信号机制的发现与肾性贫血药物治疗进展[J].药学进展，2019，43（12）：914-921.
[23] 付玉琪，涂岩，刘必成.低氧诱导因子-脯氨酸羟化酶抑制剂治疗肾性贫血的研究进展[J].中华肾脏病杂志，2020， 36（9）：726-730.
[24] 王睿，胡洪涛，胡双，等.罗沙司他治疗慢性肾脏病贫血患者的Meta分析[J].临床肾脏病杂志，2019，19（12）：871-876.
[25] 李宏彬，梁军，马强.罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J].中国医药导报，2020， 17（8）：178-181.